科兴制药引进产品贝伐珠单抗获尼日利亚上市批准

Core Viewpoint - The collaboration between Kexing Pharmaceutical and Dongyao Pharmaceutical has led to the approval of a biosimilar product, Bevacizumab injection, by the Nigerian Food and Drug Administration, marking a significant advancement in the company's strategy in the African pharmaceutical market [1] Group 1 - The approved Bevacizumab injection is indicated for the treatment of metastatic colorectal cancer, advanced or metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer [1] - The approval signifies an important step for the company in establishing its presence in the core pharmaceutical market of Africa [1]